BCEIE › News › LALPATHLAB

M&A

Dr. Lal Path Labs: Update on Acqui s i tion of stake in S N Genelab Private Limited

Dr. Lal Path Labs (LALPATHLAB) filed a disclosure titled "Update on Acqui s i tion of stake in S N Genelab Private Limited". The company is valued at about ₹33,613 crore.

BCEIE News Desk · Published 1 Oct 2026, 07:49 pm IST · Filing received 1 Oct 2026, 07:32 pm IST

What happened

Dr. Lal Path Labs (LALPATHLAB) filed a disclosure with the exchanges on 1 October 2026 at 07:32 PM titled "Update on Acqui s i tion of stake in S N Genelab Private Limited".

From the filing: "the captioned subject and in continuation to our earlier intimation dated September 24 , 2026 , wherein we have informed that the Board of Directors of the Company has approved for acquisition of stake in S N Genelab Private Limited (" SN Gene ") ."

Company snapshot

Dr. Lal Path Labs is a mid-cap company in the Healthcare sector, with a market value of about ₹33,613 crore.

The stock last traded at ₹2,005.1, against a 52-week range of ₹1,272.6–₹2,038.6 (1.6% below the high).

Before this filing the shares had moved +0.8% over the month and +18.2% over three months. Average daily turnover over the last 20 sessions was about ₹59.45 crore.

Promoters held 53.19% at the end of Q1 FY27, down 0.02% points from the previous quarter. Foreign institutions owned 17.36% and domestic institutions 21.59%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY26670132.415.88
Q2 FY26731150.618.05
Q3 FY2666090.55.42
Q4 FY26703131.37.86
Q1 FY27798169.510.15

What history shows

This is not the company's first m&a disclosure: BCEIE has 5 earlier filings of this kind on record since May 2026.

Across 115 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +1.0% over five days; 63% of them rose the next day.

Market-wide, 1,941 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

  • Regulatory approvals, completion of the deal and its effect on revenue and margins.
  • 4 November 2026: Board meeting — Financial Results/Other business matters.

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Dr. Lal Path Labs Ltd.